stockrowBioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
Follow BCRX
Alert me
BioCryst Pharmaceuticals, Inc. (BCRX) EBITDA
BioCryst Pharmaceuticals, Inc.'s EBITDA for fiscal 2025 was $338.0M, compared with −$12.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$313.5M. Over the past ten years it has ranged from −$176.9M (fiscal 2021) to $338.0M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 4 consecutive fiscal years. BioCryst Pharmaceuticals, Inc. ranks 78th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $338.0M | — |
| FY2024 | −$12.8M | — |
| FY2023 | −$112.3M | — |
| FY2022 | −$148.8M | — |
| FY2021 | −$176.9M | — |
| FY2020 | −$173.9M | — |
| FY2019 | −$98.6M | — |
| FY2018 | −$92.5M | — |
| FY2017 | −$55.7M | — |
| FY2016 | −$47.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $98.8M | — |
| Mar 2026 | −$700.1M | — |
| Dec 2025 | $259.7M | 820.36% |
| Sep 2025 | $28.2M | (4.11%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| PBH Prestige Consumer Healthcare Inc. compare | $330.9M |
| ANIP ANI Pharmaceuticals, Inc. compare | $236.2M |
| XERS Xeris Biopharma Holdings, Inc. compare | $52.9M |
| RGC Regencell Bioscience Holdings Limited compare | −$12.5M |
| ALVO Alvotech compare | −$84.5M |
| TRLV Trulieve Cannabis Corp. compare | −$104.9M |
| BCRX BioCryst Pharmaceuticals, Inc. | −$313.5M |
| PRGO Perrigo Company plc compare | −$1.2B |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$3.3B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on BCRX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement